Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,738 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Group 3 Placebo Clear all
Not listed Phase 4 Interventional

The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites

NCT02755701
View directory record Official record
Conditions
Cirrhosis, Ascites
Interventions
Branched-chain Amino Acid, Placebo
Drug
Lead sponsor
Soonchunhyang University Hospital
Other
Eligibility
19 Years to 70 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Sep 30, 2026, 7:02 PM EDT
Recruiting Phase 2 Interventional

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

NCT07610395
View directory record Official record
Conditions
Rhinovirus Infection
Interventions
VPV 1000 mg, VPV 500 mg, Placebo
Drug · Other
Lead sponsor
Altesa Biosciences, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
37
States / cities
Mobile, Alabama • Tempe, Arizona • Inglewood, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)

NCT00659841
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal, Hay Fever
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

NCT04937829
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
5 mg BI 1569912, 20 mg BI 1569912, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Garden Grove, California • Torrance, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Sep 30, 2026, 7:02 PM EDT
Not listed Not applicable Interventional

Neuroma Injections to Treat Restless Legs Syndrome - RCT

NCT00656110
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml, Normal saline - 1ml
Drug
Lead sponsor
Lowcountry Infectious Diseases
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2009 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults

NCT00644293
View directory record Official record
Conditions
Pharyngitis, Tonsillitis
Interventions
azithromycin (Zithromax), placebo, azithromycin SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Clearwater, Florida • Boise, Idaho • Meridian, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Sep 30, 2026, 7:02 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

NCT07503444
View directory record Official record
Conditions
Rett Syndrome
Interventions
fenfluramine hydrochloride, Placebo
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
5 Years to 35 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 2 Interventional

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

NCT00696332
View directory record Official record
Conditions
ALS
Interventions
Talampanel, placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
San Francisco, California • Kansas City, Kansas • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2011 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Results available

Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction

NCT01063855
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction
Interventions
Placebo, Dapoxetine, PDE5I (phosphodiesterase-5 inhibitor)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Male only
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Decatur, Alabama • Huntsville, Alabama • Englewood, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Not applicable Interventional

Harnessing Placebo Effects in Methadone Treatment

NCT02941809
View directory record Official record
Conditions
Opioid-use Disorder, Opioid-Related Disorders
Interventions
Open-Label Placebo (OLP)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

NCT07141199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-8736, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

NCT01494987
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Glimepiride, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Microalgae Extract PhaeoSOL Combined With Natural Stimulant on Cognitive Function and Gaming Performance of Video Gamers

NCT04851899
View directory record Official record
Conditions
Cognitive Function, Video Gamers
Interventions
Phaeosol low dose, Phaeosol high dose, Placebo
Dietary Supplement
Lead sponsor
Microphyt
Industry
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Sep 30, 2026, 7:02 PM EDT
Terminated Phase 3 Interventional

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer

NCT02664077
View directory record Official record
Conditions
Stage III (IIIB or IIIC) Colon Cancer
Interventions
Regorafenib, Placebo
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
51
States / cities
Orange, California • Santa Rosa, California • Vallejo, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

NCT02431767
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
4
States / cities
Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

NCT03345836
View directory record Official record
Conditions
Crohn's Disease
Interventions
Matching Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Sep 30, 2026, 7:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Resveratrol to Enhance Vitality and Vigor in Elders

NCT02123121
View directory record Official record
Conditions
Mitochondrial Function, Physical Function
Interventions
Resveratrol 1000 mg/day, Resveratrol 1500 mg/day, Vegetable cellulose, All groups
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Not applicable Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

NCT00348309
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
41
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT03904693
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions
FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
26
States / cities
Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Sep 30, 2026, 7:02 PM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

NCT05758415
View directory record Official record
Conditions
Rotator Cuff Tendinopathy
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
La Mesa, California • Van Nuys, California • Winter Park, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 30, 2026, 7:02 PM EDT
Not listed Phase 2 Interventional

Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue

NCT00651417
View directory record Official record
Conditions
Localized Breast Cancer, Localized Prostate Cancer, Patients Receiving External Beam Radiotherapy
Interventions
Organic Germanium, Placebo
Dietary Supplement
Lead sponsor
Arizona Oncology Services
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

NCT03000348
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cysteamine, Placebo Oral Capsule
Drug
Lead sponsor
NovaBiotics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Tucson, Arizona • San Francisco, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 30, 2026, 7:02 PM EDT